{"DataElement":{"publicId":"6774626","version":"1","preferredName":"London Deauville Criteria Point Scale Based Upon Excluding FDG Avid Non-Lymphoma Lesion Outcome Score","preferredDefinition":"Score information related to a 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma based on excluding FDG avid non-lymphoma lesion.","longName":"6774576v1.0:6774625v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6774576","version":"1","preferredName":"London Deauville Criteria Point Scale Base Upon Exclusion Fludeoxyglucose F-18 Avidity Negation Lymphoma Lesion Outcome","preferredDefinition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma._The most important or necessary part of something._Used to indicate that an event is to immediately follow another event._The deliberate act of omission._A positron-emitting radiopharmaceutical containing radioactive 2-deoxy-2-[18F] fluoro-D-glucose. With similar cell uptake as glucose (high in tumor cells), fludeoxyglucose F 18 is not dephosphorylated and further metabolized. (NCI04)_Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody._An operation in which a term denies or inverts the meaning of another term or construction._A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._The result of an action.","longName":"6774573v1.0:6774574v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"6774573","version":"1","preferredName":"London Deauville Criteria Point Scale","preferredDefinition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.","longName":"C99723","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"London Deauville Criteria Point Scale","conceptCode":"C99723","definition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A828489-DCC0-559D-E053-F662850AFBCA","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"ONEDATA","dateModified":"2019-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6774574","version":"1","preferredName":"Base Upon Exclusion Fludeoxyglucose F-18 Avidity Negation Lymphoma Lesion Outcome","preferredDefinition":"The most important or necessary part of something.:Used to indicate that an event is to immediately follow another event.:The deliberate act of omission.:The radioactive form of glucose used in positron emission tomography (PET), a diagnostic imaging procedure.:Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.:An operation in which a term denies or inverts the meaning of another term or construction.:A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.:A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.:The result of an action.","longName":"6774574v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Base","conceptCode":"C48055","definition":"The most important or necessary part of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Upon","conceptCode":"C65137","definition":"Used to indicate that an event is to immediately follow another event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Exclusion","conceptCode":"C82931","definition":"The deliberate act of omission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Fludeoxyglucose F-18","conceptCode":"C964","definition":"A positron-emitting radiopharmaceutical containing radioactive 2-deoxy-2-[18F] fluoro-D-glucose. With similar cell uptake as glucose (high in tumor cells), fludeoxyglucose F 18 is not dephosphorylated and further metabolized. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Avidity","conceptCode":"C16297","definition":"Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A828489-DCD8-559D-E053-F662850AFBCA","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"ONEDATA","dateModified":"2019-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A828489-DCE9-559D-E053-F662850AFBCA","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6774625","version":"1","preferredName":"London Deauville Criteria Point Scale Score","preferredDefinition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"6774625v1.0","context":"Alliance","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6774624","version":"1","preferredName":"London Deauville Criteria Point Scale Score","preferredDefinition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C99723:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"London Deauville Criteria Point Scale","conceptCode":"C99723","definition":"A 5 point scale devised to assess the response to treatment of Hodgkin and Aggressive Non-Hodgkin Lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A82DC57-AD63-313D-E053-F662850A3058","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"ONEDATA","dateModified":"2019-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A82DC57-AD74-313D-E053-F662850A3058","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Deauville score based on excl","type":"Preferred Question Text","description":"Deauville score based on excluding FDG avid non-lymphoma lesion","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A835B2B-BB4D-4863-E053-F662850ACB1E","latestVersionIndicator":"Yes","beginDate":"2019-06-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-04","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}